Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 14/20 | 0.59 |
| ▸ | MAPK3 | P27361 | 7/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.58 |
| ▸ | RAF1 | P04049 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31382816 | 1.00 | KRAS (0.59) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL31527344 | 1.00 | KRAS (0.59) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL29321556 | 1.00 | KRAS (0.59) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL29321759 | 0.98 | KRAS (0.56) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL30873453 | 0.94 | KRAS (0.59) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL29321567 | 0.94 | KRAS (0.59) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL31243086 | 0.94 | MAPK3 (0.58) | KRASMAPK3MAPK1 | |
| SCHEMBL31527044 | 0.93 | KRAS (0.60) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL30873477 | 0.92 | MAPK3 (0.57) | KRASMAPK3MAPK1 | |
| SCHEMBL29321614 | 0.92 | MAPK3 (0.57) | KRASMAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028358-A1 | SUBSTITUTED HETEROAROMATIC AMINES AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2026-01-29 | — | — | US | disclosed |
| WO-2025076523-A1 | RAS INHIBITORS AND METHODS OF USE THEREOF | KESTREL THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024083168-A1 | OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028358-A1 | SUBSTITUTED HETEROAROMATIC AMINES AND USES THEREOF | HRAS, KRAS, BCL6 | KRAS 2/4885MAPK3 631/4885MAPK1 1326/4885 |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | AZI2, HDAC5, HDAC4 | KRAS 1190/4885MAPK3 3866/4885MAPK1 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.